438481-01-7

Basic information

• Product Name: Benzamide, 4-(1,1-dimethylethyl)-N-(2-hydroxy-1,1-dimethylethyl)-
• CAS NO: 438481-01-7
• Molecular Formula: C15H23NO2
• Molecular Weight: 249.353
• Mol File: 438481-01-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzamide, 4-(1,1-dimethylethyl)-N-(2-hydroxy-1,1-dimethylethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzamide, 4-(1,1-dimethylethyl)-N-(2-hydroxy-1,1-dimethylethyl)-(438481-01-7)
• EPA Substance Registry System: Benzamide, 4-(1,1-dimethylethyl)-N-(2-hydroxy-1,1-dimethylethyl)-(438481-01-7)

Safety Data

• Hazardous Substances Data: 438481-01-7(Hazardous Substances Data)

Upstream product

• 124-68-5 2-Amino-2-methyl-1-propanol 
• 1710-98-1 p-tert-butyl benzoyl chloride 
• 98-73-7 4-(1,1-dimethylethyl)benzoic acid 

Downstream Products

• 1242157-07-8 5-tert-butyl-2-(4,4-dimethyl-4,5-dihydro-oxazol-2-yl)-benzaldehyde 
• 1242157-08-9 2-(4-(tert-butyl)-2-(1,3-dioxan-2-yl)phenyl)-4,4-dimethyl-4,5-dihydrooxazole 
• 1242157-09-0 2-(4-tert-butyl-2-1,3-dioxinan-2-yl-6-fluoro-phenyl)-4,4-dimethyl-4,5-dihydro-oxazole 
• 1433851-36-5 3-(acetoxymethyl)-2-(6-tert-butyl-8-fluoro-1-oxophthalazin-2(1H)-yl)pyridin-4-ylboronic acid 
• 1433852-40-4 (2-(6-tert-butyl-8-fluoro-1-oxophthalazin-2(1H)-yl)-4-(6-(1-ethyl-1H-pyrazol-4-ylamino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)pyridin-3-yl)methyl acetate 
• 1433846-72-0 6-tert-butyl-2-[4-[6-[(1-ethylpyrazol-4-yl)amino]-4-methyl-5-oxo-pyrazin-2-yl]-3-(hydroxymethyl)-2-pyridyl]-8-fluoro-phthalazin-1-one 
• 1433855-51-6 (2-(6-tert-butyl-8-fluoro-1-oxophthalazin-2(1H)-yl)-4-(1-methyl-5-(5-methylisoxazol-3-ylamino)-6-oxo-1,6-dihydropyridazin-3-yl)pyridin-3-yl)methyl acetate 
• 1433847-78-9 6-tert-butyl-8-fluoro-2-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methylisoxazol-3-yl)amino]-6-oxo-pyridazin-3-yl]-2-pyridyl]phthalazin-1-one 
• 1242156-59-7 6-(tert-butyl)-8-fluorophthalazin-1(2H)-one 
• 1242156-60-0 2-(6-tert-butyl-8-fluoro-1-oxophthalazin-2(1H)-yl)-6-chlorobenzaldehyde 
• 1242156-61-1 6-tert-butyl-2-(3-chloro-2-(hydroxymethyl)phenyl)-8-fluorophthalazin-1(2H)-one 
• 1242156-24-6 6-tert-butyl-8-fluoro-2-(2-(hydroxymethyl)-3-(1-methyl-5-(5-(4-methylpiperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)phenyl)phthalazin-1(2H)-one 
• 1433859-79-0 dibenzyl (2-(6-tert-Butyl-8-fluoro-1-oxophthalazin-2(1H)-yl)-4-(1-methyl-5-(5-methylisoxazol-3-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-3-yl)methyl phosphite 
• 1433859-86-9 dibenzyl (2-(6-tert-butyl-8-fluoro-1-oxophthalazin-2(1H)-yl)-4-(1-methyl-5-(5-methylisoxazol-3-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-3-yl)methyl phosphate 

Relevant articles and documents

Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target Activity

Bruton's tyrosine kinase (Btk) is thought to play a pathogenic role in chronic immune diseases such as rheumatoid arthritis and lupus. While covalent, irreversible Btk inhibitors are approved for treatment of hematologic malignancies, they are not approved for autoimmune indications. In efforts to develop additional series of reversible Btk inhibitors for chronic immune diseases, we sought to differentiate from our clinical stage inhibitor fenebrutinib using cyclopropyl amide isosteres of the 2-aminopyridyl group to occupy the flat, lipophilic H2 pocket. While drug-like properties were retained - and in some cases improved - a safety liability in the form of hERG inhibition was observed. When a fluorocyclopropyl amide was incorporated, Btk and off-target activity was found to be stereodependent and a lead compound was identified in the form of the (R,R)- stereoisomer.

Inhibitors of Bruton's Tyrosine Kinase

This application discloses 5-phenyl-1H-pyridin-2-one, 6-phenyl-2H-pyridazin-3-one, and 5-Phenyl-1H-pyrazin-2-one derivatives according to generic Formulae I-III: wherein, variables Q, R, X, X′, Y1, Y2, Y2′, Y3, Y4, Y5, m, and n are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formulae I-III and at least one carrier, diluent or excipient.